Applied Therapeutics Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Applied Therapeutics stock.
View analyst ratings for Applied Therapeutics or view top-rated stocks.

Wall Street analysts have given Applied Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Applied Therapeutics.

Applied Therapeutics, Inc. (NASDAQ:APLT) announced its earnings results on Monday, May, 10th. The company reported ($1.00) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.01) by $0.01.
View Applied Therapeutics' earnings history.

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APLT stock has decreased by 40.2% and is now trading at $17.70.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued 12-month target prices for Applied Therapeutics' shares. Their forecasts range from $18.00 to $85.00. On average, they expect Applied Therapeutics' stock price to reach $45.50 in the next year. This suggests a possible upside of 157.1% from the stock's current price.
View analysts' price targets for Applied Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Applied Therapeutics include MorphoSys (MOR), Xencor (XNCR), Deciphera Pharmaceuticals (DCPH), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), Amarin (AMRN), Indivior (INVVY), Constellation Pharmaceuticals (CNST), NGM Biopharmaceuticals (NGM), PMV Pharmaceuticals (PMVP), Avid Bioservices (CDMO), MacroGenics (MGNX), Zymeworks (ZYME), Prelude Therapeutics (PRLD) and Harmony Biosciences (HRMY).
View all of APLT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS) and Raytheon Technologies (RTX).

(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Applied Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (2.50%), Emerald Advisers LLC (2.18%) and Alliancebernstein L.P. (0.05%). Company insiders that own Applied Therapeutics stock include Charles Silberstein, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends for Applied Therapeutics.

APLT stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, and Alliancebernstein L.P.. Company insiders that have bought Applied Therapeutics stock in the last two years include Real Estate Equitie Alexandria, and Stacy J Kanter.
View insider buying and selling activity for Applied Therapeutics or or view top insider-buying stocks.

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLT stock can currently be purchased for approximately $17.70.

Applied Therapeutics has a market capitalization of $461.63 million. The company earns $-93,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

Applied Therapeutics employs 24 workers across the globe.

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]